Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

neogen corp. - NEOG

NEOG

Close Chg Chg %
4.60 -0.21 -4.57%

Closed Market

4.39

-0.21 (4.57%)

Volume: 12.56M

Last Updated:

Apr 17, 2025, 4:00 PM EDT

Trade Now

Company Overview: neogen corp. - NEOG

NEOG Key Data

Open

$4.60

 Day Range

4.32 - 4.62

52 Week Range

3.87 - 18.58

 Market Cap

N/A

Shares Outstanding

NaN

 Public Float

216.44M

Beta

N/A

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

N/A

Yield

N/A

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

8.85M

  

NEOG Performance

1 Week
 
 -21.33%
 
1 Month
 
 -50.40%
 
3 Months
 
 -62.02%
 
1 Year
 
 -62.19%
 
5 Years
 
 -86.71%
 

NEOG Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About neogen corp. - NEOG

Neogen Corp. engages in the provision of development, manufacture, and marketing of food and animal safety products. It operates through the Food Safety and Animal Safety segments. The Food Safety segment consists of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, drug residues, and levels of general sanitation. The Animal Safety segment includes a line of consumable products marketed to veterinarians and animal health product distributors. The company was founded on June 30, 1981 and is headquartered in Lansing, MI.

NEOG At a Glance

Neogen Corp.
620 Lesher Place
Lansing, Michigan 48912
Phone 1-800-232-5333 Revenue 924.22M
Industry Medical Specialties Net Income -9,421,000.00
Sector Health Technology 2024 Sales Growth 12.375%
Fiscal Year-end 05 / 2025 Employees 2,917
View SEC Filings

NEOG Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.08
Price to Book Ratio 0.906
Price to Cash Flow Ratio 81.977
Enterprise Value to EBITDA 18.032
Enterprise Value to Sales 3.876
Total Debt to Enterprise Value 0.253

NEOG Efficiency

Revenue/Employee 316,839.904
Income Per Employee -3,229.688
Receivables Turnover 5.342
Total Asset Turnover 0.202

NEOG Liquidity

Current Ratio 3.818
Quick Ratio 2.592
Cash Ratio 1.108

NEOG Profitability

Gross Margin 50.057
Operating Margin 8.377
Pretax Margin -1.548
Net Margin -1.019
Return on Assets -0.206
Return on Equity -0.30
Return on Total Capital -0.233
Return on Invested Capital -0.233

NEOG Capital Structure

Total Debt to Total Equity 28.823
Total Debt to Total Capital 22.374
Total Debt to Total Assets 19.769
Long-Term Debt to Equity 28.583
Long-Term Debt to Total Capital 22.188
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Neogen Corp. - NEOG

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
468.46M 527.16M 822.45M 924.22M
Sales Growth
+12.03% +12.53% +56.01% +12.37%
Cost of Goods Sold (COGS) incl D&A
253.40M 284.15M 416.49M 461.59M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
21.04M 23.69M 88.38M 121.23M
Depreciation
13.29M 14.09M 17.29M 26.28M
Amortization of Intangibles
7.75M 9.60M 71.08M 94.95M
COGS Growth
+14.20% +12.13% +46.58% +10.83%
Gross Income
215.06M 243.01M 405.95M 462.63M
Gross Income Growth
+9.57% +13.00% +67.05% +13.96%
Gross Profit Margin
+45.91% +46.10% +49.36% +50.06%
2021 2022 2023 2024 5-year trend
SG&A Expense
140.89M 184.40M 368.44M 385.21M
Research & Development
16.25M 17.05M 26.04M 22.48M
Other SG&A
124.64M 167.35M 342.40M 362.73M
SGA Growth
+9.42% +30.88% +99.81% +4.55%
Other Operating Expense
- - - -
-
Unusual Expense
(157.00K) (220.00K) (300.00K) 18.54M
EBIT after Unusual Expense
74.33M 58.84M 37.81M 58.89M
Non Operating Income/Expense
942.00K 1.37M (3.90M) 2.48M
Non-Operating Interest Income
1.61M 1.27M 3.17M 6.36M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 55.96M 75.67M
-
Interest Expense Growth
- - - +35.23%
-
Gross Interest Expense
- - 55.96M 75.67M
-
Interest Capitalized
- - - -
-
Pretax Income
75.27M 60.21M (22.04M) (14.30M)
Pretax Income Growth
+4.10% -20.01% -136.61% +35.10%
Pretax Margin
+16.07% +11.42% -2.68% -1.55%
Income Tax
14.39M 11.90M 828.00K (4.88M)
Income Tax - Current - Domestic
9.05M 10.99M 10.57M 10.19M
Income Tax - Current - Foreign
4.88M 5.14M 9.49M 14.41M
Income Tax - Deferred - Domestic
523.00K (4.08M) (19.27M) (27.34M)
Income Tax - Deferred - Foreign
(65.00K) (151.00K) 41.00K (2.15M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
60.88M 48.31M (22.87M) (9.42M)
Minority Interest Expense
- - - -
-
Net Income
60.88M 48.31M (22.87M) (9.42M)
Net Income Growth
+2.37% -20.65% -147.34% +58.81%
Net Margin Growth
+13.00% +9.16% -2.78% -1.02%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
60.88M 48.31M (22.87M) (9.42M)
Preferred Dividends
- - - -
-
Net Income Available to Common
60.88M 48.31M (22.87M) (9.42M)
EPS (Basic)
0.5717 0.4486 -0.1211 -0.0435
EPS (Basic) Growth
+1.02% -21.53% -127.00% +64.08%
Basic Shares Outstanding
106.50M 107.68M 188.88M 216.48M
EPS (Diluted)
0.5684 0.4472 -0.1211 -0.0435
EPS (Diluted) Growth
+1.03% -21.32% -127.08% +64.08%
Diluted Shares Outstanding
107.12M 108.02M 188.88M 216.48M
EBITDA
95.21M 82.31M 125.89M 198.65M
EBITDA Growth
+10.81% -13.55% +52.94% +57.80%
EBITDA Margin
+20.32% +15.61% +15.31% +21.49%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 11.167
Number of Ratings 4 Current Quarters Estimate -0.04
FY Report Date 05 / 2025 Current Year's Estimate -2.22
Last Quarter’s Earnings -0.05 Median PE on CY Estimate N/A
Year Ago Earnings -0.04 Next Fiscal Year Estimate -0.09
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 3 4 4
Mean Estimate -0.04 -0.03 -2.22 -0.09
High Estimates -0.03 -0.02 -2.13 -0.05
Low Estimate -0.05 -0.04 -2.26 -0.11
Coefficient of Variance -20.41 -33.33 -2.73 -30.09

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Neogen Corp. - NEOG

Date Name Shares Transaction Value
Jan 17, 2025 David H. Naemura CFO 61,434 Open market or private purchase of non-derivative security Non-derivative transaction at $11.11 per share 682,531.74
Dec 3, 2024 David H. Naemura CFO 12,911 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 3, 2024 David H. Naemura CFO 46,634 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.14 per share 659,404.76
Nov 6, 2024 Thierry Bernard Director 17,207 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 6, 2024 Thierry Bernard Director 5,620 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $14.44 per share 81,152.80
Oct 30, 2024 Catherine E. Woteki Director 3,552 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 30, 2024 James P. Tobin Director 3,552 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 30, 2024 James P. Tobin Director 27,474 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $13.81 per share 379,415.94
Oct 30, 2024 Catherine E. Woteki Director 7,474 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $13.81 per share 103,215.94
Oct 30, 2024 Aashima Gupta Director 5,917 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $13.81 per share 81,713.77
Oct 30, 2024 Aashima Gupta Director 3,552 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 30, 2024 Ronald D. Green Director 3,552 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 30, 2024 Ronald D. Green Director 12,781 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $13.81 per share 176,505.61
Oct 30, 2024 Ralph A. Rodriguez Director 3,552 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 30, 2024 Ralph A. Rodriguez Director 7,474 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $13.81 per share 103,215.94
Oct 10, 2024 Catherine E. Woteki Director 2,071 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 10, 2024 Ronald D. Green Director 2,071 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 10, 2024 Ralph A. Rodriguez Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 10, 2024 Ralph A. Rodriguez Director 2,071 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 10, 2024 James P. Tobin Director 2,071 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Neogen Corp. in the News